We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer.
- Authors
Asamer, Eva; Szkandera, Joanna; Gibiser, Paul; Lembeck, Anna Lena; Stojakovic, Tatjana; Kornprat, Peter; Lackner, Caroline; Winder, Thomas; Schlick, Konstantin; Stöger, Herbert; Gerger, Armin; Pichler, Martin; Stotz, Michael
- Abstract
Background and aim: The aim of this study was to investigate the prognostic relevance of plasma amylase and lipase concerning survival of patients suffering from metastatic pancreatic cancer (PC).Method: This retrospective study included 351 patients with metastatic PC, who were treated in a single academic institution. Cancer-specific survival (CSS) was analyzed using the Kaplan-Meier method. To further evaluate the prognostic significance of lipase and amylase, univariate and multivariate values were calculated using Cox proportional models.Results: In univariate analysis, an increased amylase level was associated with shorter CSS in PC patients (hazard ratio HR = 1.258; 95% confidence interval CI = 1.011-1.566; p = 0.039). In multivariate analysis, including gender, age, CA19-9 and administration of chemotherapy, increased amylase levels prevailed as an independent prognostic factor for CSS (HR = 1.373; 95%CI = 1.004-1.878; p = 0.047).Conclusions: Plasma amylase was found to be an independent prognostic factor in patients with metastatic PC. The results indicate that amylase might represent a novel and useful marker for better patient stratification in PC management.
- Subjects
BLOOD plasma; LIPASES; PANCREATIC cancer; AMYLASES; MULTIVARIATE analysis
- Publication
Wiener Klinische Wochenschrift, 2018, Vol 130, Issue 19/20, p569
- ISSN
0043-5325
- Publication type
Article
- DOI
10.1007/s00508-018-1383-3